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Background/introduction
Currently, thermal ablation via transcranial MRI-guided
focused ultrasound is restricted to centrally-located
regions in the brain. This limitation is the result of skull
heating when the focal region is steered to more periph-
eral regions in the brain, along with other factors such as
limitations in beam steering in the currently-available clin-
ical brain focused ultrasound systems. The treatment
envelope could be expanded if the time averaged acoustic
power needed for ablation could be reduced.
Methods
The introduction of ultrasound contrast agents – pre-
formed microbubbles that are injected intravenously –
can reduce the power needed to ablate tissue. These
commercially-available microbubble agents respond
strongly to an acoustic field, even at low intensities, and
greatly magnify the resulting bioeffects.
Results and conclusions
This presentation will provide a summary of animal data
obtained in small animals and in nonhuman primates at
our institution and by others that tested contrast-
enhanced ultrasound ablation. Overall, these studies
have demonstrated that ablation can be achieved at
time-averaged acoustic power levels at least an order of
magnitude less than what is needed for thermal ablation.
The huge reduction in acoustic power that can be
achieved with ablation combined with ultrasound contrast
agents may enable a substantial increase in the “treatment
envelope” for transcranial focused ultrasound systems.
New methods are being developed to control the proce-
dure and to ensure that unwanted tissue effects do not
occur outside of the focal region. These developments,
along with other unresolved issues with this mode of abla-
tion will be topics for discussion.
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